View printer-friendly version << Back

Masimo Recognized as Top 10 Innovator in Medical Device Industry

June 28, 2006
Masimo's patents are used as the basis for innovation 1,322% more than the industry average

Irvine, California June 28, 2006 - Masimo Corporation, the inventor of Pulse CO-Oximetry™ and Read-Through Motion and Low Perfusion pulse oximetry ranked 7th overall in the Medical Device Industry in ipIQ's 2006 Patent Scorecard™.  The Patent Scorecard is an industry-by-industry ranking of corporate innovation and combines a series of indicators to arrive at patent quality, technological strength and breadth of impact.  It has historically been published in MIT's Technology Review and tracks the patent portfolios of more than 2,500 of the world's top technology firms.

ipIQ's Current-Impact Index™, or CII, showcases the broader significance of a company's patents by examining how impactful its patents are across the industry and in specific product categories in the most recent product cycles by measuring how frequently a company's patents are referenced as prior inventions by other patents.  A CII of 100 represents average frequency.  Masimo's CII was calculated to be 1,422, which means that Masimo's patents are referenced 1,322% more often than average.  Masimo's CII score was more than 10 times the average for the medical device sector.

"Masimo's performance is stellar both within the medical device space and compared across every sector," stated Eric Gillespie, Executive Vice President and COO of ipIQ.  "The Current-Impact Index is a quality measure designed to illustrate the strength of a company's technology portfolio.  Masimo's Current-Impact Index was the highest score of the 2,500 plus companies included in the Patent Scorecard."

Joe E. Kiani, CEO and Chairman of Masimo stated, "Masimo was founded on the basis that to improve patient care and reduce cost of care, breakthroughs were necessary in the area of noninvasive vital signs monitoring.  All of our peers were focusing on engineering longer battery life and smaller foot print conventional monitors, and while that is a worthy effort, we believed it should not be put in front of the real task of making accurate and reliable noninvasive vital signs monitors, which required inventions.  We set out to solve a problem that the industry thought was unsolvable and our innovations have changed clinicians' expectations of noninvasive monitors and dramatically improved patient care and reduced cost of care." 

Mike Petterson, Vice President of Clinical Research of Masimo stated, "Our first product line, Masimo Signal Extraction Technology (SET)® pulse oximetry was the first pulse oximetry FDA cleared for accuracy during patient motion and low perfusion and has ushered in a new performance standard for this critical vital sign.  Last year, we introduced the second revolution in noninvasive vital signs monitoring, which we call Rainbow™.   Like pulse oximetry, Rainbow is a spectroscopy based platform, but instead of using only two wavelengths of light, our Rainbow platform utilizes multiple wavelengths simultaneously.  So far, we have two Rainbow measurements, the noninvasive and continuous measurements of carboxyhemoglobin and methemoglobin.  We are working on additional noninvasive, continuous measurements and hope to announce others over the next few years."

About Masimo
Masimo develops innovative monitoring technologies that significantly improve patient care- helping solve "unsolvable" problems.  In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events.  Over 70 independent clinical studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations.  In 2005 Masimo introduced Rainbow SET and with it, Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions.

Masimo, founded in 1989, has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com

Masimo, SET, Signal Extraction Technology and Improving and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications are registered trademarks of Masimo Corp. Rainbow and Pulse CO-Oximetry are trademarks of Masimo Labs.


About ipIQ
ipIQ - Intellectual Property. Intelligence Quotient. -  is the world's leading Intellectual Property advisor to investment banks, technology-driven companies, and governments. With over three decades of experience, ipIQ utilizes proprietary data, tools, analytics, and technology to leverage patent-based Intellectual Property as an asset class. The Patent Scorecard is published annually.

For additional information on the Patent Scorecared™ and ipIQ, go to www.ipIQ.com.  ipIQ™, Science Linkage™, Current-Impact Index™, and Patent Scorecard™ are trademarks of ipIQ - Intellectual Property, Intelligence Quotient and are used with permission.

Contact:
Brad Langdale
949-297-7009
blangdale@masimo.com

Contact:
Jude Reter
312-205-7037
jreter@ipIQ.com

Stay up-to-date with email alerts.

Sign up for email alerts or request information by mail.

Sign up to receive email alerts whenever Masimo Corporation posts new information to the site.

Sign Up for Updates